TLR4 and colitis: These coordinated reductions in both gene and protein expression of key inflammatory mediators substantiate ACP dose-dependent capacity to inhibit TLR4/NF-κB signaling, thereby mitigating systemic inflammation along the gut–liver axis in colitis.